Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial

August 24, 2023 10:29 am Published by

Voci D, Götschi A […] Duerschmied D […] Barco S; OVID investigators. Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial. Thromb Res 2023/221:157-163. doi: 10.1016/j.thromres.2022.10.021.

Categorised in:

This post was written by sfb1425